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ABSTRACT 
COMPARISON AND APPLICATION OF METHODS TO ADDRESS CONFOUNDING BY INDICATION 
IN NON-RANDOMIZED CLINICAL STUDIES 
SEPTEMBER 2013 
CHRISTINE M FOLEY, B.S., WORCESTER STATE UNIVERSITY 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Raji Balasubramanian 
 
Objective:  The aim of this project was to apply and compare marginal structural models, and 
propensity score adjusted models with traditional Cox Proportional Hazards models to address 
confounding by indication due to the presence of time-dependent confounders. These methods 
were applied to data from approximately 120,000 women enrolled in the Women’s Health 
Initiative (WHI) to evaluate the causal effect of antidepressant medication use with respect to 
type 2 diabetes risk.  
 
Methods:  Four approaches were compared. Three traditional Cox Models were used.  The first 
used only baseline covariates.  The second used time-varying antidepressant medication use, 
BMI and presence of elevated depressive symptoms and adjusted for all other covariates 
measured at baseline.  The third used time-varying antidepressant medication use, BMI and 
presence of elevated depressive symptoms and adjusted for other baseline covariates, with 
additional adjustment for propensity to taking antidepressants at baseline.  Our fourth method 
used a Marginal Structural Cox Model with Inverse Probability of Treatment Weighting that 
included time-varying antidepressant medication use, BMI and presence of elevated depressive 
symptoms and adjusted for all other covariates measured at baseline. 
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Results:  All approaches showed an increase in diabetes risk for those taking antidepressant 
medication.  The Cox Proportional Hazards models using only baseline covariates showed the 
lowest increase in risk (OR=1.21, 95% CI 1.07 - 1.36; OR=1.16, 95% CI 1.02 - 1.32, respectively).  
Diabetes risk increased with adjustment for time-dependent confounding and results for these 
three approaches were almost identical.  All models were statistically significant.  Ninety-five 
percent confidence intervals overlapped for all 4 approaches showing they were not significantly 
different from one another.  
 
Conclusions:  Our analyses did not find a difference in estimates between traditional Cox 
Proportional Hazards Models and Marginal Structural Cox Models in the WHI cohorts.  Estimates 
of the Inverse Probability of Treatment Weights were all very close to 1 which explains why we 
observed similar results with all four approaches. 
 
 
Keywords:  Antidepressant medication, type 2 diabetes, epidemiology, marginal structural 
models, propensity score, survival analysis 
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CHAPTER I 
INTRODUCTION 
 
Diabetes is a chronic illness with serious health consequences, such as adult blindness, 
non-traumatic limb amputation, renal failure and neuropathy.  Previous literature has noted 
considerable diabetes and depression among postmenopausal women, with a prevalence rate 
that is approximately 12% for each. 1, 2  As many as 25% of individuals live with both conditions. 3  
Two separate meta-analyses demonstrated that adults with depression had a 37-60% increased 
risk of developing diabetes. 4, 5  The 2009 sub-analysis of the Melbourne Longitudinal Studies on 
Healthy Ageing (MELSHA) found that symptomatic depression predicts a 2-fold increase in 
diabetes incidence, with or without antidepressant use. 6  
Recent literature suggests an increased risk of diabetes among those who are depressed 
and on antidepressant medications. 7-10  It is increasingly important to further investigate 
whether depression or the antidepressant medication is influencing this association given that 
approximately 11% of American women take antidepressant medication, and use is rising. 11  
While the rates of use for depression treatment has remained the same, off-label use of 
antidepressants has increased significantly. 12  Examples of antidepressant off-label use include 
treatment for certain type of pain, fibromyalgia, insomnia, and general unhappiness. 
The Women’s Health Initiative (WHI) database is a valuable resource that can inform the 
association between antidepressant medication use/depression and diabetes risk in a 
population of post-menopausal women.  It is a longitudinal study with a large sample size 
containing repeated measurements for presence of elevated depressive symptoms, self-
reported diagnosis of type 2 diabetes and antidepressant medication use.   
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Ma and colleagues 13 found that elevated depressive symptoms and antidepressant 
medication use were significantly related to type 2 diabetes risk in both unadjusted and 
multivariable Cox models in the WHI.  However, the WHI is a non-randomized setting in which 
there is the potential for several time-dependent confounders such as BMI to influence the 
causal relationship between antidepressant use and diabetes risk (Figure 1).  In other words, 
participants with increased BMI or depression could be more likely to be on antidepressants in 
the future. Moreover, BMI and depression can also significantly influence future diabetes risk. 
Thus, a naïve analysis to evaluate the causal relationship between antidepressant use and 
diabetes risk could result in biased estimates of the effects of antidepressant medication use by 
misattributing the effects of time-dependent confounders such as BMI to treatment.   
When research interest lies in the causal effect of a time varying exposure on outcome, 
in the presence of time-modified confounding, traditional Cox models can result in biased 
estimates that do not necessarily have causal interpretation (Figure 1). 14-16 In an observational 
study, it is difficult to guarantee balance of important potential confounding variables such as 
age, race/ethnicity, and gender between groups because participants were not randomized to 
either antidepressant medication users or non-users.  If more participants in one level of the 
confounding variable are on treatment because of the influence of a time-dependent 
confounder, we could falsely see a treatment effect when there is not one.  A solution to this 
problem is the use of marginal structural models.  Marginal structural models are appropriate 
when you have time-dependent confounding with a time-varying exposure.  They aim to break 
the association between the exposure and confounder and provide balance between treatment 
and control across levels of the confounding variable.  These methods can also be applied if your 
time-dependent confounder is influenced by prior treatment and is thus an intermediate. 
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The objective of this work was to apply and compare results obtained from standard 
approaches, such as multivariable Cox models and propensity score adjusted Cox models to 
those obtained from the application of IPTW marginal structural model methods developed for 
causal inference applicable to non-randomized settings. These methods were applied to data 
from approximately 68,000 women enrolled in the WHI-OS and approximately 52,000 women 
enrolled in the WHI-CT to evaluate the causal effect of antidepressant medication use with 
respect to type 2 diabetes risk.  
 The paper is organized as follows: In the Methods section, we describe our study 
population, timing of our measurements, instruments used and our modeling approaches.  We 
also describe our outcome measures, along with time varying exposures and confounders 
considered.  In the Results section, we present results obtained by applying the four approaches 
we used to estimate the causal effect of antidepressant medication use on development of 
diabetes.  In the Discussion section, we compare and contrast our results with the results of 
other investigators who have used similar approaches in different applications. Our analyses 
contribute to the comparison of these models to standard techniques as it applies to the 
analysis of large scale epidemiological models and non-randomized observational studies. 
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CHAPTER II 
METHODS 
 
The Women’s Health Initiative (WHI) 
The WHI enrolled 161,808 participants into clinical trials (WHI-CT) and an observational 
study (WHI-OS) between 1993 and 1998. 17-20  The eligibility criteria included: postmenopausal 
women aged 50 to 79 years, reliable/mentally competent, and expected survival and local 
residency for at least 3 years. Exclusion criteria included current alcoholism, drug dependency, 
and dementia or other conditions that would limit full participation in the study.  The WHI 
enrolled 68,132 participants into clinical trials (WHI-CT), and 93,676 women were enrolled into 
an observational study (WHI-OS). 17 The WHI-CT included: the Dietary Modification Trial (DMT), 
the Hormone Trial (HT, estrogen-alone or estrogen plus progestin) and the combination of DMT 
and HT. Participants enrolled in one of the clinical trial components were screened for eligibility 
and invited to join the calcium and vitamin D (CaD) component at their first or second annual 
clinic visits.  Medication use, presence of elevated depressive symptoms, and diabetes status 
were collected from participants over an average of 7.6 years of follow-up. The study was 
approved by the institutional review boards of participating WHI institutions, and institutional 
review board exemption for the current investigation was obtained at the University of 
Massachusetts Medical School.  
Outcome Ascertainment 
The outcome variables in our analysis were diabetes status and time to development of 
diabetes.  Diabetes status was assessed by self-report at baseline and at each annual follow-up 
visit.  Time to diabetes was calculated as the interval between study enrollment and 
development of diabetes as evidenced by an annual medical history update, or censorship 
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(death or end of study participation). Margolis and colleagues 21 found patient self-report of 
diabetes to be a reliable indicator of diagnosed diabetes, validated with medication and 
laboratory data assessments.  
Time Varying Exposure 
Our main exposure of interest was antidepressant medication use, measured at 
baseline and year 3 in the WHI-OS and baseline, year 1, year 3, year 6 and year 9 in the WHI-CT 
arm.  Medication use was collected using the F44 Medication form, at which time case 
managers transcribed label information from medication bottles brought in by the WHI 
participants.  Antidepressants include the following major groups: 1) Selective serotonin 
reuptake inhibitors (SSRIs); 2) Monoamine oxidase inhibitors (MAOIs); 3) Tricyclic 
antidepressants (TCAs); 4) Tetracyclics; 5) Serotonin/norepinephrine reuptake inhibitors (SNRIs); 
6) Aminoketones; 7) Triazolopyridines; and 8) Dibenzoxazepine.  A dichotomous indicator of 
antidepressant medication use was then created. 13  We did not perform any analyses by class of 
medication.  
Time Varying Confounders 
The primary time varying confounders considered in this analysis were (1) presence of 
elevated depressive symptoms and (2) BMI.  Elevated depressive symptoms were measured 
using the 6-item Center for Epidemiological Studies Depression Scale (CES-D).  A participant was 
determined to have elevated depressive symptoms if their score was 5 or higher on the CES-D.  
Presence of elevated depressive symptoms was available at baseline and year 3 in the WHI-OS.  
In the WHI-CT, presence of elevated depressive symptoms was assessed in a small percentage of 
participants after baseline.  For this reason, analysis for this cohort adjusted only for presence of 
elevated depressive symptoms at baseline. BMI was available at baseline and year 3 in the WHI-
OS and baseline, year 1, year 3, year 6 and year 9 in the WHI-CT.   
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Other confounders 
Models adjusted for age, race/ethnicity (White vs. Other), education (<=high school; high 
school or GED; >= high school, but less than 4 years of college; 4 or more years of college), 
minutes of recreational physical activity per week, total energy intake, hormone therapy use 
(never, former, current), family history of diabetes (no, yes, don’t know) and smoking status 
(never smoked, past smoker, current smoker), all measured at baseline.  Many of these could 
have potentially been time-varying if we had repeated measurements. 
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CHAPTER III 
STATISTICAL ANALYSIS 
 
Analysis datasets 
WHI OS 
A total of 68,169 women were available for analysis in this cohort after exclusions for 
self-reported diagnosis of diabetes at baseline (n=3902), missing baseline diabetes status 
(n=109), missing race/ethnicity information (n=252), or missing information on presence of 
elevated depressive symptoms (n=10,427), antidepressant medication use or BMI (n=6899) at 
baseline or year 3 (Figure 2).  After exclusions, a total of 3624 women reported diagnosis of type 
2 diabetes during follow-up.  Information on the time-varying exposure (antidepressant use) and 
the time varying confounders (BMI, presence of elevated depressive symptoms) were available 
at baseline and year 3.  
WHI CT 
Although we had data from baseline to year 9 in the WHI-CT, we used data from 
baseline to year 3 for this analysis because presence of elevated depressive symptoms was only 
measured on a small percentage of women after year 1.  The time-varying exposure 
(antidepressant use) and the time varying confounder (BMI) were available at baseline, year 1 
and year 3.  Models adjusted for presence of elevated depressive symptoms at baseline.  
Women were excluded from analysis if they had a self-reported diagnosis of diabetes at baseline 
(n=3265), missing diabetes status at baseline (n=36), or missing race/ethnicity information 
(n=125).  We also excluded women who were missing information on baseline presence of 
elevated depressive symptoms (n=531), antidepressant medication use or BMI at baseline, year 
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1 or year 3 (n=11,849) (Figure 2), resulting in 52,326 women available for analysis.  After 
exclusions, a total of 4171 women reported diagnosis of type 2 diabetes during follow-up. 
We compared results from 4 different approaches in estimating the association 
between presence of elevated depressive symptoms and antidepressant medication use with 
the risk of type 2 diabetes.  We used three traditional Cox Proportional Hazards Models 
(Approaches 1-3) and a Marginal Structural Cox Model (Approach 4) to estimate the association 
in the WHI-OS and WHI-CT separately.   
Approach 1 - Cox Proportional Hazards Model 
Approach 1 used traditional Cox Proportional Hazards Models to estimate the 
association of antidepressant medication use at baseline on diabetes risk, adjusting for baseline 
factors including: presence of elevated depressive symptoms, BMI, age, ethnicity, education, 
minutes of recreational physical activity per week, total energy intake, hormone therapy use, 
family history of diabetes and smoking status.   
Approach 2 - Extended Cox Proportional Hazards Model 
Approach 2 used an extended Cox Model to model the association of time-varying 
antidepressant medication use on diabetes risk adjusting for time-varying presence of elevated 
depressive symptoms (WHI-OS) or baseline presence of elevated depressive symptoms (WHI-
CT), time-varying BMI, and adjusted for age, ethnicity, education, minutes of recreational 
physical activity per week, total energy intake, hormone therapy use, family history of diabetes 
and smoking status, all measured at baseline.   
Approach 3 - Extended Cox Proportional Hazards Model Adjusting for Propensity 
Approach 3 used an extended Cox Model with time-varying exposure and confounders, 
as in Approach 2, with additional adjustment for propensity to taking antidepressants at 
baseline.  The time-invariant propensity score was calculated by predicting baseline 
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antidepressant use from a logistic model that included presence of elevated depressive 
symptoms, BMI, age, ethnicity, education, minutes of recreational physical activity per week, 
total energy intake, hormone therapy use, family history of diabetes and smoking status, all 
measured at baseline.   
Approach 4 – Marginal Structural Cox Proportional Hazards Model 
We followed the basic framework of Hernan and colleagues 
14
 for fitting marginal 
structural models for survival analysis by estimating the IPTW weights.  Four logistic regression 
models were used to calculate the probabilities that constructed the weights.  Models 1 and 2 
estimated the probability of not being on antidepressants.  To account for the effect of 
censoring, models 3 and 4 estimated the probability of not being censored.  Each model was 
adjusted for the following confounders: age, ethnicity, education, minutes of recreational 
physical activity per week, total energy intake, hormone therapy use, family history of diabetes 
and smoking status, all measured at baseline.  In the WHI-CT analysis, models were also 
adjusted for which clinical trial a woman was participating in.  The numerator of the weight is a 
function of baseline covariates.  The denominator used the same baseline covariates, and added 
the most recent time-varying value as well.  To relax the linearity assumption, we added a 
quadratic function of time, month and month2, as additional covariates in the model.  
Estimating the probability of not being on antidepressants – Models 1 and 2 
Using a dataset with one row of data per participant per measurement time point, we 
estimated the probability of not being on antidepressant medication at each time point as a 
function of presence of elevated depressive symptoms and BMI, as well as other confounders.  
Model 1 estimated the probability of not being on antidepressants as a function of baseline 
covariates.  Model 2 included baseline covariates, as well as the most recent value of the time-
varying covariates.  
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Estimating the probability of not being censored – Models 3 and 4 
We used a dataset expanded to one row of data per participant for each month until 
their time to diabetes because censoring was a time to event outcome.  A woman who did not 
develop diabetes had 1 row of data per month until they were censored.  In the last row of data 
for each woman, their censoring or diabetes indicator was equal to 1, and equal to 0 in all rows 
previous.  In this way, the time to diabetes or time to censoring indicator for each woman was 
utilized.  The probability of not being censored was estimated as a function of antidepressant 
medication use, presence of elevated depressive symptoms, BMI, and other confounders.  
Model 3 estimated the probability of not being censored as a function of baseline covariates.  
Model 4 included baseline covariates, as well as the most recent value of the time-varying 
covariates. 
Estimating subject- and time-specific stabilizing weights 
Models 1-4 were merged together and the weights were calculated. The IPTW are 
calculated as a cumulative product that multiplies the probability of antidepressant medication 
use over time for each participant.  The probability for each patient remains constant over time 
until there is a new measurement point and then that probability is multiplied by the new 
probability.  Since the probability of not being censored was a time to event outcome, we 
calculated the cumulative product over all months for each participant.  The numerator of the 
stabilizing weights was calculated as the probability of antidepressant use multiplied by the 
probability of being uncensored for each participant for each month.  The denominator of the 
stabilizing weights was calculated in the same manner, and the ratio of the two was the 
stabilizing weight.  
Marginal Structural Cox Model 
11 
 
The final step in our analysis was to run a pooled logistic regression model using the PROC 
GENMOD procedure in SAS as a way to fit the weighted Cox model. 14  An independent working 
correlation matrix was specified in the model.  The model was weighted by the stabilized IPTW 
estimates.  This procedure produced hazard ratios for the risk of diabetes for those using 
antidepressant medications compared to those who were not.  The pooled logistic regression 
model estimated the association as a function of time-varying antidepressant medication use, 
time-varying presence of elevated depressive symptoms (OS) or baseline presence of elevated 
depressive symptoms (CT), time-varying BMI, and other confounders. To relax the linearity 
assumption with respect to time, we included both a linear and quadratic function of time, as 
additional covariates in the model. 
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CHAPTER IV 
RESULTS 
 
Table 1 presents the baseline characteristics of our study population, by antidepressant 
medication use.  In both cohorts, the mean age was approximately 63 years old (63.59 (OS); 
62.77 (CT)).  Women were primarily White (86.5% (OS); 84.4% (CT)) and most had greater than 
high school education (80% (OS); 76.4% (CT)).  Approximately 30% of women on antidepressants 
had elevated depressive symptoms (28.2% (OS); 29.8% (CT)).  A greater percentage of 
antidepressant medication users than non-users reported current use of hormone replacement 
therapy (64.9% vs. 49.7% (OS); 53.6% vs. 36.3% (CT)).  Antidepressant users and non-users had 
approximately equal proportions that reported a family history of diabetes (30% vs. 30.6% (OS); 
31.4% vs. 31.6% (CT)) or current smoking (7.2% vs. 5.4% (OS); 9.0% vs. 7.2% (CT)).  Mean BMI 
was very similar for those on antidepressants vs. not (27.91 vs. 26.70 (OS); 29.41 vs. 28.48 (CT)). 
Table 2 presents development of diabetes for those who were exposed to 
antidepressant medication compared to those who were not for all 4 modeling approaches.  The 
Cox PH model including only baseline antidepressant medication use and baseline presence of 
elevated depressive symptoms produced a crude diabetes rate ratio of 1.26 (95% CI 1.12-1.41) 
indicating a significant increase in diabetes risk without adjusting for other factors. The standard 
Cox model in Approach 1 does not adjust for time-dependent confounding and yielded a hazard 
ratio of 1.21 (95% CI 1.07 – 1.36) in the OS cohort.  The Cox models in Approach 2 and Approach 
3 using time-varying antidepressant medication use, time-varying presence of elevated 
depressive symptoms and time-varying BMI, yielded almost identical results (HR=1.33, 95% CI 
1.20-1.48; HR=1.31; 95% CI 1.17 - 1.45, respectively) and showed an increased risk of developing 
diabetes relative to Approach 1.  The hazard ratio and confidence interval for the marginal 
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structural Cox model (Approach 4) was almost identical to the extended Cox models in Approach 
2 and Approach 3 (HR=1.34; 95% CI 1.20 - 1.50) demonstrating that, in this application, the 
marginal structural Cox model yielded similar results to the traditional extended Cox model.  The 
confidence intervals for all 4 models overlap indicating the models are not significantly different 
than one another. 
As in the WHI OS, all models in the WHI-CT showed a significant increase in diabetes risk 
for those exposed to antidepressant medications vs. those who were not.  The crude diabetes 
rate ratio (HR=1.17, 95% CI 1.04-1.31) was very similar to the results in Approach 1.  The hazard 
ratios and confidence intervals for Approaches 2, 3, and 4 were almost identical, and like the OS 
cohort the risk estimate is greater than in  Approach 1, which did not adjust for time-dependent 
confounding (HR: 1.16;95% CI 1.02-1.32).  By adjusting for time-dependent confounding, the 
hazard ratios for Approach 2 and Approach 3 increased from Approach 1 (HR=1.28, 95% CI 1.14-
1.43; HR=1.26, 95% CI 1.12-1.41, respectively).  The marginal structural model in Approach 4 
again estimated a hazard ratio almost identical to that of the extended Cox models (HR=1.27, 
95% CI 1.13-1.43).  The confidence intervals for all 4 models overlap, indicating they are not 
significantly different from one another.  
Table 3 presents the full model inverse probability of treatment-weighted estimates for 
the marginal structural models for the causal effect of antidepressant medication use on 
diabetes risk.  All covariates including antidepressant medication use, ethnicity, education, 
minutes of physical activity per week, family history of diabetes, hormone therapy use, smoking 
status, presence of elevated depressive symptoms, BMI, age, and total energy intake are 
significant in the model for the WHI-OS, and all but total energy intake for the WHI-CT.   
Table 4 presents the distributions of the IPTW weights, namely the estimated 
probability of having one’s own observed treatment history and censoring history at follow-up 
14 
 
time points.  The probability of remaining uncensored was very close to 1 for both cohorts at 
each follow-up time point given both the baseline and time-varying covariates.  There was 
variation in the probability of having one’s own observed treatment history, but the mean and 
median were very close to 1 at 36 month follow-up in the WHI-OS and 12 month follow-up in 
the WHI-CT.   
Table 5 presents an estimate of variation in the primary exposure and time-dependent 
confounder variables.  Participants not on antidepressants remained pretty stable over time, but 
there was some switching on and off the drug.  Of the 60,297 participants who were not taking 
antidepressants at baseline, 95% of them were also not taking them at year 3.  Of the 3,321 
participants who were taking antidepressants at baseline, 69.35% of them were also taking 
them at year 3.  Approximately 30% of those who were on antidepressants at baseline were not 
taking them at year 3 and almost 5% of those not taking them at baseline were on 
antidepressants at year 3.   
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CHAPTER V 
DISCUSSION 
 
 We compared Marginal Structural Cox Proportional Hazards Models to standard Cox 
Models to estimate the association of antidepressant medication use and presence of elevated 
depressive symptoms on diabetes risk in the WHI.  Previous research has shown a marginal 
structural modeling approach to be an unbiased method when you have a time-varying 
confounder, such as BMI, that is affected by previous exposure.   
Our analyses did not find a difference in estimates between traditional Cox Proportional 
Hazards Models and Marginal Structural Cox Models in the WHI cohorts.  The hazard ratios and 
confidence intervals for the 4 models we compared in the WHI OS and the 4 models we 
compared in the WHI CT were all very similar.  As our models increased in complexity, first 
taking into account the time-varying confounding (Cox PH Models) and then time-dependent 
confounding (Marginal Structural Models), the estimates were very similar to the crude rate 
ratio.  This suggests that the time-varying confounders did not have much effect on our 
outcome.  The confidence intervals overlapped, indicating they were not significantly different 
from one another.  Our estimates of the IPTW weights were all very close to 1 which drives the 
observed similarity in results using marginal structural models when compared to Cox 
Proportional Hazards Models.  
 A limitation of this work is that we had a limited amount of measurement points to work 
with in this dataset.  The WHI-OS had 2 measurement time points.  The WHI-CT had more time 
points available, but we were only able to utilize 3 of them because of insufficient numbers of 
participants with enough data for our main exposure variable after baseline.  This allowed for 
long periods of time where we had no new information on their antidepressant medication use, 
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BMI, presence of elevated depressive symptoms, or other covariates.  We may have missed 
important information on our time-varying exposure or covariates during that time.  Participants 
could have gone off antidepressants 1 year after enrolling in the study, but we would not have 
accounted for that until year 3 when we had new data on that subject.  Participants could also 
have gone off antidepressants and then gone back on during the period of time where we did 
not have new data.  Because presence of elevated depressive symptoms was measured on only 
a small percentage of participants after baseline, our models for the WHI-CT could not use 
presence of elevated depressive symptoms as a time varying exposure.  
Our analyses contribute to the literature by demonstrating that marginal structural 
models may not be required over traditional methods of analysis in all applications.  A certain 
level of time-dependent confounding may need to exist in your dataset for these complicated 
methods to be called for.  An important area for further study would be to assess what level of 
time-dependent confounding is necessary for marginal structural models to be a better 
approach than standard methods.  
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Table 1. Summary of Baseline Characteristics of the Study Sample  
(Continued on to next few pages) 
 Antidepressant Medication Use 
 No Yes Total 
WHI-OS 
BMI    
Mean (SD) 26.70 (5.48) 27.91 (5.97) 26.79 (5.53) 
Median (IQR) 25.64 (6.32) 26.74 (7.19) 25.71 (6.39) 
Age    
Mean (SD) 63.70 (7.26) 62.14 (7.25) 63.59 (7.27) 
Median (IQR) 64 (11) 62 (12) 64 (11) 
Minutes of recreational physical activity per week 
Mean (SD) 206.93 (186.19) 172.12 (174.80) 204.48 (185.63) 
Median (IQR) 165 (225) 135 (212.5) 165 (225) 
Years from enrollment to developing diabetes   
Mean (SD) 7.69 (1.47) 7.56 (1.54) 7.68 (1.47) 
Median (IQR) 7.93 (1.99) 7.88 (2.00) 7.92 (1.99) 
Total energy intake    
Mean (SD) 1533.05 (599.86) 1615.08 (640.37) 1538.82 (603.16) 
Median (IQR) 1461.29 (730.06) 1533.19 (765.75) 1465.41 (733.40) 
Presence of elevated depressive symptoms   
No 54923 (86.7%) 3440 (71.8%) 58363 (85.6%) 
Yes 8457 (13.3%) 1349 (28.2%) 9806 (14.4%) 
Ethnicity    
White 54614 (86.2%) 4380 (91.5%) 58994 (86.5%) 
Other 8766 (13.8%) 409 (8.5%) 9175 (13.5%) 
Education    
<= high school 2409 (3.8%) 189 (4%) 2598 (3.8%) 
High school or GED 9765 (15.5%) 752 (15.9%) 10517 (15.5%) 
>=High school, but less 
than 4 years of college 22587 (35.9%) 1765 (37.2%) 24352 (36%) 
4 or more years of 
college 28152 (44.7%) 2036 (42.9%) 30188 (44.6%) 
Hormone therapy use    
Never 18423 (29.6%) 738 (15.7%) 19161 (28.6%) 
Former 12885 (20.7%) 914 (19.4%) 13799 (20.6%) 
Current 30931 (49.7%) 3055 (64.9%) 33986 (50.8%) 
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 Antidepressant Medication Use 
 No Yes Total 
Family history of diabetes 
No 41656 (66%) 3114 (65.2%) 44770 (65.9%) 
Yes 18923 (30%) 1463 (30.6%) 20386 (30%) 
Don't know 2569 (4.1%) 198 (4.1%) 2767 (4.1%) 
Smoking status    
Never Smoked 32614 (52%) 2188 (46.2%) 34802 (51.6%) 
Past Smoker 26685 (42.6%) 2207 (46.6%) 28892 (42.9%) 
Current Smoker 3370 (5.4%) 339 (7.2%) 3709 (5.5%) 
    
WHI-CT 
BMI    
Mean (SD) 28.48 (5.64) 29.41 (5.99) 28.54 (5.67) 
Median (IQR) 27.57 (7.20) 28.35 (7.96) 27.62 (7.23) 
Age    
Mean (SD) 62.83 (6.93) 61.77 (6.94) 62.77 (6.94) 
Median (IQR) 63 (11) 61 (11) 63 (11) 
Minutes of recreational physical activity per week 
Mean (SD) 163.22 (168.95) 138.94 (159.22) 161.72 (168.47) 
Median (IQR) 125 (215) 85 (195) 120 (215) 
Years from enrollment to developing diabetes   
Mean (SD) 7.99 (1.68) 7.86 (1.73) 7.98 (1.68) 
Median (IQR) 8.02 (1.73) 8.00 (1.91) 8.02 (1.76) 
Total energy intake    
Mean (SD) 1716.72 (679.54) 1819.65 (711.86) 1723.00 (682.00) 
Median (IQR) 1618.25 (832.50) 1716.34 (870.79) 1623.68 (833.68) 
Presence of elevated depressive symptoms   
No 42582 (86.7%) 2238 (70.2%) 44820 (85.7%) 
Yes 6557 (13.3%) 949 (29.8%) 7506 (14.3%) 
Ethnicity    
White 41243 (83.9%) 2924 (91.7%) 44167 (84.4%) 
Other 7896 (16.1%) 263 (8.3%) 8159 (15.6%) 
Education    
<= high school 2302 (4.7%) 144 (4.5%) 2446 (4.7%) 
High school or GED 8991 (18.4%) 587 (18.5%) 9578 (18.4%) 
>=High school, but less 
than 4 years of college 19110 (39.1%) 1236 (39%) 20346 (39.1%) 
4 or more years of 
college 18426 (37.7%) 1199 (37.9%) 19625 (37.7%) 
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 Antidepressant Medication Use 
 No Yes Total 
Hormone therapy use 
Never used hormones 17793 (37.9%) 662 (21.6%) 18455 (36.9%) 
Past hormone user 12122 (25.8%) 760 (24.8%) 12882 (25.7%) 
Current hormone user 17057 (36.3%) 1644 (53.6%) 18701 (37.4%) 
Family history of diabetes   
No 31282 (63.9%) 2022 (63.7%) 33304 (63.9%) 
Yes 15378 (31.4%) 1004 (31.6%) 16382 (31.4%) 
Don't know 2280 (4.7%) 147 (4.6%) 2427 (4.7%) 
Smoking status    
Never Smoked 25547 (52.5%) 1429 (45.2%) 26976 (52.1%) 
Past Smoker 19615 (40.3%) 1445 (45.7%) 21060 (40.6%) 
Current Smoker 3495 (7.2%) 285 (9%) 3780 (7.3%) 
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Table 2. Hazard Ratios Comparing Cox Proportional Hazards Models to Marginal Structural 
Models 
 
 Observational Cohort (OS) (N=68,169 - the number of patients with complete data for time 
varying antidepressant medication use, presence of elevated depressive symptoms, and BMI 
up until year 3, and baseline values for other covariates) 
 Crude Diabetes 
Rate Ratio 
Approach 1 Approach 2 Approach 3 Approach 4 
 Cox PH Model  
(using baseline 
antidepressant 
medication use 
and baseline 
presence of 
elevated 
depressive 
symptoms) 
Cox PH Models  
(using baseline 
values of all 
predictors) 
 
 
Cox PH Models  
(using time 
varying 
antidepressant 
medication use, 
presence of 
elevated 
depressive 
symptoms, 
and BMI; 
baseline values 
for other 
covariates) 
Cox PH Models  
(using time 
varying 
antidepressant 
medication use, 
presence of 
elevated 
depressive 
symptoms, and 
BMI; adjusted for 
propensity score 
and baseline 
values for other 
covariates) 
Marginal 
Structural Models 
(using time 
varying 
antidepressant 
medication use, 
presence of 
elevated 
depressive 
symptoms, and 
BMI; baseline 
values for other 
covariates) 
Predictor HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
Antidepressant 
medication use 
up to year 3 
1.26 
(1.12-1.41) 
1.21 
(1.07 - 1.36) 
1.33 
(1.20 - 1.48) 
1.31 
(1.17 - 1.45) 
1.34 
(1.20 - 1.50) 
 Clinical Trial (CT) (N=52,326-the number of patients with complete data for time varying 
antidepressant medication use and BMI up until year 3, and baseline values for presence of 
elevated depressive symptoms other covariates) 
Antidepressant 
medication use 
up to year 3 
1.17 
(1.04-1.31) 
1.16 
(1.02 - 1.32) 
1.28 
(1.14 - 1.43) 
1.26 
(1.12 - 1.41) 
1.27 
(1.13 - 1.43) 
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Table 3. Inverse Probability of Treatment-Weighted Estimates of The Parameters Of A Marginal 
Structural Model For The Causal Effect Of Antidepressant Medication Use On Diabetes Risk 
(Continued on to next few pages) 
 
 Estimate SE 95% CI HR (95% CI) P-value 
WHI-OS 
Antidepressant 
medication use 0.293 0.056 0.185 - 0.402 
1.34  
(1.20-1.50) <.0001 
Ethnicity        
White -0.580 0.043 -0.664 - -0.496 
0.56  
(0.51-0.61) <.0001 
Other       . 
Education        
<= high school 0.348 0.076 0.198 - 0.498 
1.42  
(1.22-1.65) <.0001 
High school or 
GED 0.279 0.051 0.180 - 0.379 
1.32  
(1.20-1.46) <.0001 
>=High school, 
but less than 4 
years of college 0.214 0.041 0.133 - 0.294 
1.24  
(1.14-1.34) <.0001 
4 or more years 
of college       . 
Minutes of 
physical activity 
per week -0.001 0.000 -0.001 - 0.000 
1.00  
(0.9991-0.9996) <.0001 
Relative had 
adult diabetes        
No -0.388 0.085 -0.554 - -0.222 
0.68  
(0.57-0.80) <.0001 
Yes 0.397 0.084 0.232 - 0.562 
1.49  
(1.26-1.75) <.0001 
Don't know       . 
Hormone therapy 
use        
Never 0.115 0.041 0.034 - 0.196 
1.12  
(1.03-1.22) 0.0053 
Former 0.130 0.045 0.041 - 0.219 
1.14  
(1.04-1.24) 0.0041 
Current       . 
Smoking status        
Never Smoked -0.165 0.073 -0.307 - -0.023 
0.85  
(0.74-0.98) 0.0227 
Past Smoker -0.126 0.074 -0.270 - 0.018 
0.88  
(0.76-1.02) 0.0869 
Current Smoker       . 
Presence of 
elevated 
depressive 
symptoms 0.089 0.045 0.000 - 0.177 
1.09  
(1.00-1.19) 0.049 
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 Estimate SE 95% CI HR (95% CI) P-value 
BMI 0.080 0.002 0.076 - 0.084 
1.08  
(1.08-1.09) <.0001 
Age 0.018 0.003 0.013 - 0.023 
1.02  
(1.01-1.02) <.0001 
Baseline total 
energy intake        
4.87- 1100.54 -0.205 0.048 -0.300 - -0.110 
0.81  
(0.74-0.90) <.0001 
1100.55- 1437.42 -0.238 0.049 -0.333 - -0.143 
0.79  
(0.72-0.87) <.0001 
1437.44- 1828.01 -0.174 0.048 -0.268 - -0.080 
0.84  
(0.76-0.92) 0.0003 
>=1828.02        
WHI-CT 
Antidepressant 
medication use 0.242 0.059 0.126 - 0.357 
1.27  
(1.13-1.43) <.0001 
Ethnicity        
White -0.462 0.041 -0.542 - -0.381 
0.63  
(0.58-0.68) <.0001 
Other        
Education        
<= high school 0.315 0.072 0.174 - 0.455 
1.37  
(1.19-1.58) <.0001 
High school or 
GED 0.196 0.049 0.101 - 0.292 
1.22  
(1.11-1.34) <.0001 
>=High school, 
but less than 4 
years of college 0.219 0.041 0.139 - 0.298 
1.24  
(1.15-1.35) <.0001 
4 or more years 
of college        
Minutes of 
physical activity 
per week -0.001 0.000 -0.001 - 0.000 
0.999  
(0.999-1.00) <.0001 
Relative had 
adult diabetes        
No -0.358 0.075 -0.505 - -0.210 
0.70  
(0.60-0.81) <.0001 
Yes 0.323 0.074 0.177 - 0.468 
1.38  
(1.19-1.60) <.0001 
Don't know        
Hormone therapy 
use        
Never 0.167 0.045 0.078 - 0.255 
1.18  
(1.08-1.29) 0.0002 
Former 0.165 0.049 0.069 - 0.261 
1.18  
(1.07-1.30) 0.0008 
Current        
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 Estimate SE 95% CI HR (95% CI) P-value 
Smoking status 
Never Smoked -0.186 0.063 -0.310 - -0.062 
0.83  
(0.73-0.94) 0.0033 
Past Smoker -0.203 0.065 -0.330 - -0.076 
0.82  
(0.72-0.93) 0.0018 
Current Smoker        
Presence of 
elevated 
depressive 
symptoms 0.088 0.045 0.000 - 0.176 
1.09  
(1.00-1.19) 0.0511 
BMI 0.073 0.002 0.069 - 0.077 
1.08  
(1.07-1.08) <.0001 
Age 0.020 0.003 0.015 - 0.025 
1.02  
(1.02-1.03) <.0001 
Baseline total 
energy intake        
4.87- 1100.54 -0.037 0.049 -0.133 - 0.059 
0.96  
(0.88-1.06) 0.4477 
1100.55- 1437.42 -0.037 0.046 -0.127 - 0.053 
0.96  
(0.88-1.05) 0.4167 
1437.44- 1828.01 -0.060 0.044 -0.146 - 0.026 
0.94  
(0.86-1.03) 0.17 
1828.02- 
23020.93        
Participated in 
hormone therapy 
trial 0.096 0.052 -0.006 - 0.198 
1.10  
(0.99-1.22) 0.0656 
Participated in 
dietary 
modification trial 0.095 0.054 -0.010 - 0.201 
1.10  
(0.99-1.22) 0.0756 
Participated in 
calcium/  
vitamin D 
supplementation -0.028 0.034 -0.095 - 0.039 
0.97  
(0.91-1.04) 0.4128 
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Table 4. Estimated Probability of Having One’s Own Observed Treatment History And Censoring 
History At Follow-Up 
 
 N Mean SD Median 
Quartile 
Range Minimum Maximum 
WHI-OS        
36 Months        
Probability of having observed antidepressant medication history     
given baseline 
covariates 
64048 0.91 0.05 0.92 0.06 0.48 0.99 
given time-varying 
covariates 
64048 0.91 0.06 0.92 0.06 0.36 0.99 
        
Probability of being uncensored 
given baseline 
covariates 
64099 0.99983 0.0000261 0.9998269 0.0000372 0.99968 0.99988 
given time-varying 
covariates 
64099 0.99983 0.0000262 0.9998270 0.0000374 0.99969 0.99988 
WHI-CT        
12 Months        
Probability of having observed antidepressant medication history     
given baseline 
covariates 46084 0.93 0.04 0.95 0.05 0.52 0.99 
given time-varying 
covariates 46084 0.93 0.05 0.95 0.05 0.31 0.99 
        
Probability of being uncensored 
given baseline 
covariates 46084 
0.9999997 6.4192736E-8 0.9999997 8.7696349E-8 0.9999994 0.9999998 
given time-varying 
covariates 46084 
0.9999997 6.4550241E-8 0.9999997 8.8088701E-8 0.9999993 0.9999998 
36 Months        
Probability of having observed antidepressant medication history     
given baseline 
covariates 
45235 0.86 0.09 0.88 0.10 0.25 0.99 
given time-varying 
covariates 
45235 0.86 0.09 0.88 0.10 0.20 0.99 
Probability of being uncensored 
given baseline 
covariates 
45235 0.999971 6.4295277E-6 0.999972 8.8005442E-6 0.99994 0.99998 
given time-varying 
covariates 
45235 0.999971 6.4828669E-6 0.999972 8.8476766E-6 0.99993 0.99998 
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Table 5. Estimate of Variation in Primary Exposure and Time-Dependent Confounder Variables 
(WHI-OS) 
 
Antidepressant use at 
baseline 
No antidepressant use at 
baseline 
 N (%) N (%) 
Antidepressant use at year 3 3321 (69.35%) 3083 (4.86%) 
No antidepressant use at year 3 1468 (30.65%) 60,297 (95.14%) 
 
Presence of elevated 
symptoms at baseline 
No presence of elevated 
symptoms at baseline 
Presence of elevated symptoms at year 3 4348 (44.34%) 6,333 (10.85%) 
No presence of elevated symptoms at 
year 3 5,458 (55.66%) 52,030 (89.15%) 
   
 Baseline Year 3 
 Mean (SD) Mean (SD) 
BMI 26.80 (5.54) 27.09 (5.59) 
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Figure 1. Illustration of time-dependent confounding by BMI in the association of antidepressant 
medication use and time to development of diabetes 
 
 
 
 
Figure 1 illustrates the hypothesis that there is time-varying confounding by BMI with regard to 
the association between diabetes risk and antidepressant use. Let A denote the exposure or 
antidepressant use, L denotes measured covariates such as BMI or race, U denotes unmeasured 
covariates and Y denotes the outcome of development of diabetes.  The causal graph in Figure 1 
shows that the probability of antidepressant medication use (A) depends on BMI (L), but not U. 
There is confounding, but measured covariates are sufficient to adjust for, so no unmeasured 
confounding.  The probability of antidepressant medication use at baseline (A(0)) is determined 
by baseline BMI (L(0)).  In our example, confounding is time dependent because antidepressant 
medication use vs. non-use at time 1 (A(1)) is determined by previous exposure (A(0)) and BMI 
at time 1 (L(1)).  Even though antidepressant medication use (A) and diabetes (Y) share common 
causes, the non-causal association between exposure and outcome can be blocked by 
conditioning on the BMI (L). 
 
 
  
Measured covariates (L(0))
BMI, race, smoking,
hormone therapy use
Unmeasured covariates (U(0))
Exposure (A(0))
Antidepressant 
Medication use
Outcome (Y)
Development of
diabetes
Measured covariates (L(1))
BMI, race, smoking,
hormone therapy use
Unmeasured covariates (U(1))
Exposure (A(1))
Antidepressant
Medication use
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Figure 2. Flow chart describing analytic cohort included for the investigation 
 
Exclusions:  
 377 women without race/ethnicity information   
 7,167 women with self-reported DM at baseline (3,902 from the WHI-OS arm and 
3,265 from the CT arm respectively). 
 145 women missing DM at baseline 
CT arm: 64,706    OS arm: 89,413    
161,808 Total  
154,119 Enrolled 
64,175 women 
with 
nonmissing 
information  
3624 self reported 
diabetes 
531 women 
missing baseline 
depression  
4171 self reported 
diabetes 
 
10427 women 
missing depression 
at baseline or 3 year 
followup  
78986 women with 
nonmissing 
depression at baseline 
and 3 year visit 
55,206 women 
with 
nonmissing 
information  
8969 women 
missing anti 
depression 
medication at 
baseline, 1 year or 3 
year followup 
74792 women 
with 
nonmissing 
information 
4194 women missing 
anti depression 
medication at 
baseline or 3 year 
followup 
68,169 women 3 
year visit within 
½ year of 3 year 
mark [913-1278 
days from 
enrollment] 
3918 women 3 
year visit more 
than ½ year from 
3 years post 
enrollment date 
52,326 women 
with 
nonmissing 
information  
2880 women 
missing BMI at 
baseline, 1 year or 3 
year followup 
72,087 women 
with 
nonmissing 
information  
2705 women 
missing BMI at 
baseline, 1 year or 3 
year followup 
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APPENDIX 
SAS CODE TO FIT THE MARGINAL STRUCTURAL COX PROPORTIONAL HAZARDS MODEL 
 
Here I provide details on how to set up the data, along with some SAS code to perform 
the Marginal Structural Cox Proportional Hazards analysis.  The first part of the analysis uses the 
proc logistic procedure to calculate the probability of not being on antidepressants (Models 1 
and 2).  Data in the file ‘iptw’ contains 1 record per woman for each time point included in the 
analysis.  For example, in the WHI-OS dataset, we have measurements at baseline and year 3.  
Each woman has two records, one for baseline and one for year 3.  Next we use the proc logistic 
procedure to calculate the probability of not being censored (Models 3 and 4).  In the data file 
‘iptw2’ the data has been expanded so that a woman has 1 record per month until her time to 
diabetes or time to censoring.  The dataset ‘main’ merges Models 1-4 together to calculate our 
IPTW weights.  This again will be an expanded dataset so a woman has 1 record per month until 
her time to diabetes or time to censoring.  The dataset ‘main_w’ contains the inverse probability 
of treatment weights and is the dataset used to run the marginal structural model analysis.  Last, 
we use the proc genmod procedure to fit the final pooled logistic regression model to obtain the 
estimates of our association of interest. 
At the baseline time point, the variables in Model 1 are basically a subset of Model2.  
Model 1 includes only baseline covariates and Model 2 includes baseline and follow-up values 
for the same variables.  Because baseline is the start of our analysis, there are no follow-up 
values to consider at that time point.  For that reason, the weights at baseline are going to be 1 
and here we run a logistic regression model estimating the probability of not being on 
antidepressants for the follow up (month 36) time point only.   
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Antidep is a dichotomous 0/1 indicator of the participant being on or off 
antidepressants.  Model 1 includes a time-dependent intercept and baseline covariates:  
presence of elevated depressive symptoms (base_depression), BMI (base_bmi), Age 
(age), Ethnicity (ethnic_cat), Education (educ4), Minutes of physical activity per 
week (tminwk), Total energy intake (base_energy_cat), Family history of diabetes 
(diabrel), Hormone therapy use (hormstat) and smoking status (smoking). Model 
2 includes a time-dependent intercept and baseline covariates, with the addition of the most 
recent time-dependent values (depression, bmi).   
The outcome variable in Models 3 and 4 is a dichotomous indicator of whether or not 
the participant has been censored up to that time point.  These models include as regressors 
variables for ‘month’ and ‘month2’ to relax the linearity assumption.  All available person 
months are included.  Model 3 includes baseline covariates with the addition of baseline 
antidepressant medication use, while Model 4 includes the baseline covariates as well as the 
most recent time-dependent value.   
We merge Models 1-4 together and in the following data step use the predicted values 
from those models to compute our IPTW estimates.  First, we calculate the numerator K2_0 and 
denominator K1_0 of the probability of not being censored by forming the product up to month 
t of the subject-specific values predicted in Models 3 and 4.   
We then calculate the numerator K1_0 and denominator K2_0 of the probability of not 
being on antidepressants by forming the product up to month t of the subject-specific values 
predicted in Models 1 and 2.  We multiply by that probability for participants who were not on 
antidepressants and 1-that probability for participants who were taking antidepressants from 
month 36 until time to diabetes or time to censoring.  From baseline until month 35, the 
probability of not being on antidepressants is 1.  We then use the numerators and denominators 
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of the probability of not being censored and the probability of not being on antidepressants to 
calculate the ‘stabilized’ (stabw) and ‘non-stabilized’ (nstabw) weights.  
In our last step, we use the proc genmod procedure to fit the weighted pooled logistic 
model to obtain estimates of our association of interest from our Marginal Structural Cox PH 
Model.  The outcome here is diabetes_tv which is a dichotomous indicator of whether or not 
the participant developed diabetes during that month.  The patient ID variable and the 
independent working correlation matrix (subject=id/type=ind) must be specified.  We weighted 
the model used the stabilized weights by using the ‘scwgt stabw’ statement in the procedure.  
The ‘estimate’ statement asks the procedure to report the odds ratio for our main association of 
interest which we use as our hazard ratio, in addition to the coefficients in the model.  
 
/*calculate probability of not being on antidepressants*/ 
 
/* Model 1*/ 
 
proc sort data=iptw; 
by id month; 
run; 
 
proc logistic data=iptw; 
class ethnic_cat educ4 base_energy_cat hormstat smoking diabrel; 
where month=36; 
model antidep=base_depression base_bmi age ethnic_cat educ4 tminwk 
base_energy_cat diabrel hormstat smoking; 
output out=model1 p=pandep_0_temp; 
run; 
 
/* Model 2*/ 
 
proc logistic data=iptw; 
where month=36; 
class ethnic_cat educ4 base_energy_cat energy_cat hormstat smoking 
base_energy_cat diabrel; 
model antidep=base_depression depression base_bmi bmi age ethnic_cat 
educ4 tminwk  base_energy_cat diabrel hormstat smoking; 
output out=model2 p=pandep_w_temp; 
run; 
 
/*calculate probability of not being censored*/ 
 
31 
 
/* Model 3*/ 
 
proc logistic data=iptw2; 
class ethnic_cat educ4 base_energy_cat hormstat smoking diabrel; 
model censor_tv=antidep depression bmi age ethnic_cat educ4 tminwk  
base_energy_cat diabrel hormstat smoking month month_sq; 
output out=model3 p=punc_0; 
run; 
 
/* Model 4*/ 
 
proc logistic data=iptw2; 
class ethnic_cat educ4 base_energy_cat hormstat smoking diabrel; 
model censor_tv=antidep antidepressant_tv depression bmi age ethnic_cat 
educ4 tminwk  base_energy_cat diabrel hormstat smoking depression_tv 
bmi_tv month month_sq; 
output out=model4 p=punc_w; 
run; 
 
/*merge data*/  
data main;  
merge temp1 temp2 model3(in=a) model4(in=b);  
by id month; if a=1 and b=1;  
if first.id then do; 
     pandep_0 = 1; 
     pandep_w = 1; 
end; 
if month=36 then do; 
     pandep_0=pandep_0_temp; 
     pandep_w=pandep_w_temp; 
end; 
retain pandep_0 pandep_w; 
run; 
 
/* Calculate the weights*/ 
 
data main_w; 
set main;  
by id month; 
 
/*reset variables for a new patient*/ 
if first.id then do; 
 k2_0=1; k2_w=1; 
end; 
retain k2_0 k2_w; 
 
/*inverse probability of censoring weights*/ 
else do; 
k2_0=k2_0*punc_0; 
k2_w=k2_w*punc_w; 
end; 
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/* Inverse probability of treatment weights */ 
if antidepressant_tv=0 and month>=36 then k1_0=pandep_0; 
if antidepressant_tv=0 and month>=36 then k1_w=pandep_w; 
 
if antidepressant_tv=1 and month>=36 then k1_0=(1-pandep_0); 
if antidepressant_tv=1 and month>=36 then k1_w=(1-pandep_w); 
 
if month<36 then k1_0=1; 
if month<36 then k1_w=1; 
 
 
/* Stabilized and non stabilized weights */ 
        stabw=(k1_0*k2_0)/(k1_w*k2_w); 
        nstabw=1/(k1_w*k2_w); 
 
run; 
 
/* Pooled logistic regression model to run the MSM analysis */ 
 
proc genmod data=main_w descending; 
class id ethnic_cat educ4 hormstat smoking base_energy_cat diabrel; 
model diabetes_tv=antidepressant_tv ethnic_cat educ4 tminwk diabrel 
hormstat smoking depression_tv bmi_tv age base_energy_cat month 
month_sq/ link=logit dist=bin; 
scwgt stabw; 
repeated subject=id/ type=ind; 
estimate "log O.R. antidepressant" antidepressant_tv 1 / exp; 
run; 
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